Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

Figure 1

Survival times of nude mice bearing human hepatocellular carcinoma BEL-7402 tumors treated with either high-dose doxorubicin or YSL plus high-dose doxorubicin. BEL-7402 cell suspension (1 × 107/each mouse) was subcutaneously inoculated into the right back of every nude mouse. When tumor volume research 100 mm3, they were randomly divided into different groups (n = 20). The mice were administrated i.p. for 30 days or until the death of mouse. Statistical significances of survival time were tested by Kaplan-Meier method using SPSS, and difference between the group of high dosage of ADM and the group of YSL combination group was tested by Log Rank, statistical significance was set at P < 0.05. ADM, doxorubicin or adriamycin; YSL, tripeptide tyroserleutide.

Back to article page